Diligence memo · auto-generated · as of July 2, 2026
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Marker Therapeutics, Inc. operates in Biotechnology, based in HOUSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Marker Therapeutics, Inc. has raised $30M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2024-12-23.
Most recent recorded round closed around 2024-12-23.
Valuation (modeled)modeled
Provath models Marker Therapeutics, Inc. at approximately $94M (range $32M–$153M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.56× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 18 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 5.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 74% of Biotechnology peers (4293 compared).
Modeled value ranks above 57% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.